1 Gender/Sex Disparities in the COVID-19 Cascade from Testing to Mortality: An

2 Intersectional Analysis of Swiss Surveillance Data

3 Diane Auderset^{*1,2}, Michaël Amiguet³, Carole Clair², Valérie Pittet³, Julien Riou³, Joëlle Schwarz²

4 & Yolanda Mueller¹

5 *Corresponding author

¹ Department of Family Medicine, Centre for Primary Care and Public Health (Unisanté),
 University of Lausanne, Lausanne, Switzerland

- ² Gender and Health Unit, Department of Ambulatory Care, Centre for Primary Care and Public
 Health (Unisanté), University of Lausanne, Lausanne, Switzerland
- ³ Department of Epidemiology and Health Systems, Centre for Primary Care and Public Health
- 11 (Unisanté), University of Lausanne, Lausanne, Switzerland
- 12

13 ABSTRACT

14 *Objectives* This study investigates gender and sex disparities in COVID-19 epidemiology in the

Canton of Vaud, Switzerland, focusing on the interplay with socioeconomic position (SEP) andage.

Methods We analyzed COVID-19 surveillance data from March 2020 to June 2021, using an
 intersectional approach. Negative binomial regression models assessed disparities between
 women and men, across SEP quintiles and age groups, in testing, positivity, hospitalizations, ICU
 admissions, and mortality (Incidence Rate Ratios [IRR], with 95% Confidence Intervals [CI]).

Results Women had higher testing and positivity rates than men, while men experienced more hospitalizations, ICU admissions, and deaths. The higher positivity in women under 50 was mitigated when accounting for their higher testing rates. Within SEP quintiles, gender/sex differences in testing and positivity were not significant. In the lowest quintile, women's mortality risk was 68% lower (Q1: IRR 0.32, CI 0.20-0.52), with decreasing disparities with increasing SEP quintiles (Q5: IRR 0.66, CI 0.41-1.06).

Conclusion Our findings underscore the complex epidemiological patterns of COVID-19, shaped
 by the interactions of gender/sex, SEP, and age, highlighting the need for intersectional
 perspectives in both epidemiological research and public health strategy development.

30 Keywords (5-8) COVID-19 epidemiology; Gender and sex; Social determinants of health;

31 Intersectionality; Public health strategy NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 INTRODUCTION

The COVID-19 pandemic has had heterogeneous impacts, with certain populations being 33 34 disproportionately affected. The literature on COVID-19 indicates that socioeconomically 35 disadvantaged groups face higher risks of contracting the virus and experiencing severe outcomes such as hospitalization and mortality (1-5). This risk is linked to socioeconomic 36 37 determinants, where limited income and education create conditions that elevate exposure risk 38 and susceptibility to infection (1). In many countries, studies have highlighted socioeconomic disparities in the COVID-19 cascade, both nationally (5-8) and regionally (4, 9), indicating that 39 neighborhood-level socioeconomic vulnerability shapes these disparities (10). Additionally, 40 41 substantial gender differences, particularly in labor and family domains, impact individuals throughout their lifespan, contributing to gendered socioeconomic inequalities that affect health 42 43 (11).

44 Globally, men were more likely to develop severe forms of COVID-19, resulting in higher hospitalizations and mortality rates compared to women (12-18). The origins and pathways of 45 these disparities are rooted in a complex interplay of gender-specific social processes and sex-46 47 related biological attributes. Gender, as a major social determinant, shapes life experiences and 48 health outcomes through systematic differences in roles, responsibilities, access to power, and 49 opportunities between women and men (19, 20). Gender inequalities in health arise from the 50 intricate interaction of multiple factors, including differential exposure to health risks, health-51 related behaviors, access to healthcare, and gender biases in healthcare and research (19, 21). Exploring gender and sex reveals nuanced pathways impacting the COVID-19 progression from 52 testing rates to mortality. Gender affects individuals' health behaviors, access to healthcare, 53 54 occupational exposures, and adherence to public health measures, thereby potentially affecting 55 COVID-19 exposure, testing rates, positivity, and the burden of disease (15, 22-25). Conversely, sex-related differences, such as immune responses and hormone levels, primarily influence 56 susceptibility, severity, and mortality rates of COVID-19 (13, 26, 27). Studies suggest that 57 hormones like oestrogens and progesterone, typically higher in women, offer protection against 58 59 viral infections, whereas testosterone, predominant in men, may have the opposite effect (28, 29). Additionally, men often exhibit higher ACE-2 receptor levels, used by SARS-CoV-2 to enter cells, 60 potentially explaining the more severe infection cases (26, 28, 30). 61

The significant variations in the influence of gender and sex across socioeconomic conditions and over the lifespan underscore the importance of intersectional approaches to deepen our understanding of COVID-19 epidemiology (28, 31). Building on Kimberlé Crenshaw's work, the concept of intersectionality emerges as a critical framework that clarifies the complex and multifaceted nature of individual experiences, such as their health, shaped by various forms of oppression, including class and gender inequalities (32). An intersectional perspective highlights
the intricate ways in which socially constructed categories—rooted in structural power relations—
intersect at multiple levels, often independently or simultaneously, to produce nuanced layers of
disadvantage (19, 32, 33). It helps to move beyond the consideration of isolated risk factors (34)
and focuses on identifying modifiable cause for health inequalities, offering major insights for
formulating equitable public health policies and interventions (35).

This study analyzes surveillance data from the canton of Vaud, located in the southwestern part 73 74 of Switzerland within the French-speaking region. As one of Switzerland's larger cantons by 75 population and area, it encompasses diverse urban and rural settings, representing approximately 76 one-tenth of the national population. The primary objective is to explore gender and sex disparities in the COVID-19 epidemiology cascade, from testing to mortality, including test positivity, 77 78 hospitalization, and intensive care unit (ICU) admission. We examined these disparities in the 79 context of key social determinants of health, focusing on neighborhood-based socioeconomic position (SEP) and age, through an intersectional analytical approach. We aim to uncover the 80 complex dynamics underlying these disparities and enhance our understanding of COVID-19's 81 broader epidemiology. Such knowledge, by considering gender and sex influences, 82 vulnerabilities, and diverse social determinants of health is essential for developing targeted and 83 effective public health strategies to address COVID-19 and guide responses to future pandemics 84 85 (28).

86 METHODS

87 Study design and setting

This observational retrospective study analyzed COVID-19 surveillance data from March 2020 to 88 89 the end of June 2021 of the population residing in the canton of Vaud. The first epidemic wave in Switzerland spanned from February to May 2020, characterized by low testing capacities with 90 RT-PCR tests (4, 5). The tested population primarily included symptomatic individuals, those with 91 92 known risk factors (e.g., people with comorbidities), and healthcare workers (4). Testing was expanded on June 24, 2020, to include mildly symptomatic individuals and close contacts of 93 94 infected individuals, with test costs reimbursed (5). Vaccinations began in December 2020, 95 initially for vulnerable groups, and expanded with the opening of vaccination on January 11, 2021 96 (36, 37). By June 2021, 85% of those aged 75 or older, and 53% of those aged 18 to 49 had 97 received at least one vaccine dose (38).

98 **Data**

99 Within the Swiss federal state, the Federal Office of Public Health (FOPH) oversees the 100 monitoring of transmissible diseases, including COVID-19, in collaboration with cantonal

authorities, through mandatory reporting of infectious diseases (36). Entities authorized to 101 conduct SARS-CoV-2 testing (RT-PCR and rapid antigen tests), such as general practitioners, 102 pharmacies, and testing centers, had to notify each test (negative and positive) to the FOPH. 103 104 Hospitalizations (lasting at least 24 hours) and ICU admissions due to COVID-19 were reported 105 by hospitals. Probable or confirmed COVID-19-related deaths were reported to cantonal health 106 authorities (see Supplementary Table S1 for case definitions). Population data as of December 107 31, 2020, were obtained from the cantonal office of statistics (39). The SEP of notified individuals was determined using the Swiss-SEP, an area-based indicator (40, 41). Detailed information on 108 the geocoding procedures is provided in Supplementary Section 2. 109

110 The study period spanned 69 weeks from March 2, 2020 (first notified cases in Vaud canton), to 111 June 27, 2021, marking the cessation of the cantonal hospital's surveillance system. Due to inconsistent negative test reporting prior to May 24, 2020, the dataset for the total number of tests 112 was limited to the period from May 27, 2020, to June 27, 2021, covering a span of 57 weeks. 113 114 Notifications included the date, test result (positive, negative), date of birth or age, and residential address. Additionally, the gender/sex of each individual was recorded. For hospitalization, death, 115 and PCR test notifications, the gender/sex indicator conformed to the administrative sex 116 categories, restricted to female or male in Switzerland. In contrast, rapid antigenic tests included 117 an "other" option alongside "women" and "men", acknowledging non-binary gender identities. 118 119 Consequently, we refer to this variable as "gender/sex" throughout our analysis. Duplicated 120 notifications, records with invalid residential addresses, and those missing age or gender/sex 121 information were excluded. Additionally, notifications with "other" as gender/sex (0.001% of total tests) were excluded. Age was grouped into eight categories of 10-year age bands and 80 and 122 above. For hospitalizations, ICU admissions, and deaths, ages 0 to 59 years were combined due 123 124 to low number of events in this age range.

125 The Swiss socio-economic position (Swiss-SEP)

The Swiss-SEP, an area-based socio-economic position index centered on each residential 126 127 building and incorporating neighborhood information from the surrounding 50 households, was 128 developed by the Swiss National Cohort (41) (detailed in Supplementary Section 3). The Swiss-SEP index, derived through principal component analysis, aggregates neighborhood-level data 129 from the 2000 census and 2012-2015 annual micro-census. This index utilizes key indicators as 130 131 proxies for SEP: median rent per square meter (income proxy), proportion of households led by 132 individuals with a primary education or less (education proxy), proportion of households headed by individuals in manual or unskilled jobs (occupation proxy), and the average number of persons 133 134 per room (crowding proxy). The index scores range from 0 to 100, with higher values indicating

higher SEP (40). There are 115 596 SEP neighborhoods within the geographical boundaries ofVaud canton.

137 Residential coordinates of each notification were matched with the nearest SEP neighborhood, 138 and SEP index values were categorized into guintiles from one (lowest) to five (highest). Nonresidential addresses, such as schools or nursing homes, and addresses with only ZIP code 139 140 information, were assigned the average SEP of their ZIP code area. Regarding total and positive 141 test notifications, 94% and 92% respectively, were successfully geocoded, thus assigned an address-based SEP (See Supplementary Table 4). However, notifications for hospitalization and 142 ICU admission, that contained only ZIP code information, did not receive a SEP assignment due 143 144 to the method of assigning average SEP scores to ZIP code areas, which tends to centralize 145 distribution around mean values, thereby reducing variability at the extremes of the SEP quintiles. Death notifications that could not be geocoded (39%) were likewise excluded from analyses 146 requiring SEP attribution, due to similar concerns regarding the accuracy of SEP assignment. 147

148 Statistical analysis

The distribution of notifications stratified by gender/sex, across age groups, and SEP guintiles 149 were described. Incidence rates of tests, positive tests, hospitalizations, ICU admissions, and 150 deaths were calculated weekly per 100 000 persons, stratified by gender/sex categories. 151 152 Cumulative incidence rates over the study period were similarly computed. Negative binomial regression models were used to examine the incidence rate ratios (IRR) with 95% confidence 153 intervals (CIs) between women and men, with interaction terms between sex/gender and age 154 155 groups and between SEP quintiles. These models, which can handle overdispersion of residuals, included denominators as offsets, with corresponding age and sex structure of the general 156 population as of December 31, 2020, serving as the base for all outcomes. Specifically for positive 157 tests, an additional negative binomial model using the total number of tests as the denominator 158 was formulated to investigate gender/sex-specific test positivity ratios. A similar methodology was 159 applied for ICU admissions, with hospitalizations serving as the offset. Sensitivity analyses were 160 161 conducted on death notifications, incorporating notifications from institutional locations, followed 162 by a comprehensive analysis of all death notifications, including those not precisely geocoded. Statistical analyses were conducted using R statistical software (42), and negative binomial 163 models estimated using the MASS package (43). 164

165 Data reporting standards

This research aligns with the Sex and Gender Equity in Research (SAGER) guidelines, which advocate for systematic integration of sex and gender considerations into research design, analysis, and reporting (44). Consequently, we will discuss the sex and/or gender-related mechanisms potentially influencing the findings reported within the context of Switzerland. In this

paper, the term "gender/sex" is used to acknowledge the complex interplay between these concepts from a theoretical perspective (45). This terminology effectively reflects the varied nature of surveillance data analyzed, where the indicator might represent either administrative sex or gender identity, depending on the notification type. From a methodological standpoint, gender/sex acts as a proxy capturing both gender-related aspects (e.g., behaviors) and sexrelated biological factors (e.g., hormonal differences), which may impact the outcomes studied.

176

177 **RESULTS**

178

[Table 1 – descriptive statistics]

By the end of 2020, Vaud population was 815 300, comprising 412 599 women (50.6%) and 402 701 men (49.4%) (Table 1). From March 2020 to June 2021, a total of 885 925 SARS-CoV-2 tests, 96 963 positive tests, 6 356 hospitalizations, 1 134 ICU admissions and 1 175 deaths (before excluding non-geocoded death notifications) were notified and met eligibility criteria (see Supplementary Figure 5). Although women had more tests and positive results, the majority of hospitalizations, ICU admissions, and deaths occurred among men.

In the canton of Vaud, 38% of women and 34% of men were aged 50 and above. Among women, this age group accounted for 33% of all tests and 38% of positive tests, but represented 80% of hospitalizations, 89% of ICU admissions, and 99.8% of deaths. Likewise, men aged 50 and older accounted for 32% of tests, 39% of positive tests, 86% of hospitalizations, 91% of ICU admissions, and 99.4% of deaths.

For total tests, 17% of women and 18% of men were in the lowest socioeconomic quintile (Q1), while 21% of tests for both women and men occurred in the highest quintile (Q5). Regarding positive tests, 21% for women and 20% for men were recorded in Q1, with 18% in Q5 for both. In terms of mortality, 18% of men who died were in Q1, and 14% in Q5. Among women, 12% of deaths occurred in Q1 and 15% in Q5.

195

[Fig. 1 – Weekly incidence rate overtime]

The weekly incidence of outcomes per 100 000 showed distinct patterns between women and men throughout the study period (Figure 1). Women had higher incidence rate of tests and positive tests compared to men, especially during the second wave of the pandemic. In contrast, men had higher incidence rates of hospitalizations and ICU admissions throughout the study period, though the disparity in mortality rates was less pronounced. During the third wave, while testing rates peaked, both severe outcomes and positivity rates were comparatively lower.

202

[Fig. 2 – Cumulative incidence across SEP and age groups]

The cumulative incidences of outcomes across age groups, gender/sex categories, and SEP 203 quintiles revealed distinct patterns (Figure 2). Individuals aged 20 to 39 were the most tested 204 group, whereas children under 10 were the least tested. Testing rates were higher for people 205 206 aged 80 and above compared to those aged 60-69 and 70-79. Similar patterns emerged across 207 age groups concerning positivity. For severe outcomes, prominent age-related trends were 208 observed, with older age groups experiencing higher incidence rates, though ICU admission were 209 less frequent among those aged 80 and above. Men experienced higher incidence rates of hospitalization, ICU admission, and death than women. 210

In terms of SEP quintiles (Figure 2, panel B), the cumulative incidence of testing progressively 211 212 increased from Q1 to Q5. For the cumulative incidence of positive tests, the three lowest SEP 213 quintiles (Q1-Q3) showed similar rates, with lower rates observed in the two highest quintiles (Q4-Q5). A consistent trend was observed, with women having higher cumulative incidence of both 214 tests and positive tests across all quintiles, except in Q5 where the positivity incidence was 215 216 comparable between women and men. For death notifications, men's cumulative mortality rate appeared to decrease from Q1 to Q5, whereas for women, the mortality rate was lowest in Q1 217 and Q4. Men displayed higher mortality rates across all SEP quintiles, except in Q2. 218

219

[Fig. 3 – IRR of tests and positive tests]

220 Regression analyses demonstrated distinct testing patterns between women and men across age 221 groups. Notably, women aged 20-29 (IRR 1.14, CI 1.07-1.22) and 30-39 (IRR 1.16, CI 1.09-1.24) displayed a significantly higher likelihood of undergoing testing compared to men in the same age 222 223 groups (Figure 3, left panel). Conversely, girls under 10 (IRR 0.91, CI 0.85-0.97) and women aged 60-69 (IRR 0.92, CI 0.86-0.98) and 70-79 (IRR 0.85, CI 0.80-0.91) were less likely to get tested 224 compared to their male counterparts. For incidence of positive tests per population, similar 225 gender/sex trends were observed across age groups (Figure 3, center panel). However, these 226 227 trends were not apparent when adjusting for the initial gender/sex differences in testing, as indicated by the regression results of positive tests per test (Figure 3, right panel). An exception 228 229 was observed among individuals aged 60 and older, where women were less likely to test positive per test compared to men. Specifically, women had an IRR of 0.92 in the 60-69 age group (CI 230 0.86-0.98), 0.89 in the 70-79 age group (CI 0.82-0.95), and 0.83 among those aged 80 and older 231 (CI 0.86-1.00), indicating a lower likelihood of a positive result when tested. Moreover, when 232 233 comparing women and men in similar SEP quintiles (Figure 3, red coefficients), no statistically 234 significant differences in testing and positive testing rates were found, except for women in Q3 235 who presented a slightly reduced probability of testing positive per test compared to their male 236 counterparts.

In regression models without an interaction term for gender/sex categories (Supplementary Table
6), individuals in Q5 were notably more likely to undergo testing (IRR 1.25, CI 1.19-1.30)
compared to those in Q1. Conversely, individuals in Q5 showed a decreased likelihood of testing
positive per person (IRR 0.89, CI 0.85-0.95) and testing positive per test (IRR 0.71, CI 0.68-0.74).

241

[Fig. 4 – IRR of hospitalisations]

242 Age was the strongest predictor for hospitalisations, ICU admissions and deaths, increasing age 243 being associated with higher likelihoods of these events, as shown by the regression analysis in models without an interaction term by gender/sex (Supplementary Table 6). Analyzing the 244 245 interaction of gender/sex with age (Figure 4, Panel A), women exhibited lower probabilities of 246 COVID-19 hospitalization than men across all age cohorts, although the differences were not statistically significant. The IRR for women up to 59 was 0.80 (CI 0.52-1.22), 0.49 (CI 0.18-1.36) 247 for those 60-69, 0.50 (CI 0.18-1.38) for the 70-79 age group, and 0.58 (CI 0.21-1.61) for those 80 248 249 and above. Statistical significance was achieved for ICU admissions in the under-60 cohort, where women had a 55% decreased risk (IRR 0.45, CI 0.23-0.86). Women consistently showed a lower 250 risk of ICU admissions compared to men when hospitalized (figure 4, Panel B). Women under 60 251 presented an IRR of 0.59 (CI 0.44-0.78), denoting a 41% lower risk. In the 60-69 age group, the 252 253 IRR was 0.71 (CI 0.49-1.01), with the risk reduction becoming more pronounced with advancing 254 age. Women aged 70-79 had an IRR of 0.62 (CI 0.43-0.88), while those aged 80 and over had 255 an IRR of 0.56 (CI 0.37-0.85), mirroring the risk reduction observed in the youngest age group.

256

[Fig. 5 – IRR of deaths]

Regarding mortality, individuals in Q5 had a lower likelihood of death (IRR 0.71, CI 0.54-0.95) 257 compared to those in Q1, as indicated by the regression models without a gender/sex interaction 258 term (Supplementary Table 6). This association between SEP and death persisted in the 259 260 sensitivity analysis that included nursing home residents and remained robust when extended to include non-precisely geocoded death notifications (Supplementary material S7). Lower mortality 261 262 rates among women were noted across all age groups (figure 5). Women demonstrated a reduced mortality risk compared to men of 55% at ages 60-69 (IRR 0.45, CI 0.23-0.88), 58% at ages 70-263 79 (IRR 0.42, CI 0.30-0.59), and 45% for those aged 80 and above (IRR 0.55, CI 0.46-0.66). 264 Regarding SEP, the gender/sex disparities in mortality were more pronounced in Q1, with women 265 266 having a 68% reduction in mortality risk (IRR 0.32, CI 0.20-0.52); and these disparities were not statistically significant in Q2 and Q5. Exploring the combined effects of gender/sex, age, and SEP 267 268 on mortality among older groups (70-79 and 80+), a triple interaction term was employed 269 (Supplementary Figure S8). Our findings indicate a reduction in gender/sex mortality disparities 270 with increasing SEP, as the IRR tends toward unity from the lowest to highest quintiles.

271 DISCUSSION

In the resident population of the Canton of Vaud, Switzerland, women contributed to a higher number of COVID-19 tests and positive tests than men, whereas more hospitalizations, ICU admissions, and deaths occurred among men. This finding underscores a pronounced gender/sex disparity in the pandemic's health impact, highlighting the need to explore underlying causes, such as potential biological differences, gender-specific behavioral patterns, and occupational exposures.

Individuals residing in the highest SEP neighborhoods underwent more COVID-19 testing than 278 279 those in the lowest SEP areas, accompanied by a lower likelihood of testing positive and a 280 reduced risk of mortality. These observations suggest significant socio-economic influences on health-related behaviors and resource accessibility and utilization. Notably, our intersectional 281 analysis revealed that these disparities in testing and positivity rates are consistent across women 282 283 and men within similar SEP quintiles. Moreover, the gender/sex disparities in mortality across SEP guintiles highlight the intricate interplay between socioeconomic factors and gender/sex, 284 reinforcing the value of an intersectional approach in uncovering nuanced aspects of COVID-19 285 286 epidemiology.

Moreover, age-related variations in SARS-CoV-2 testing rates between women and men were evident in our data. Women aged 20-29 and 30-39 had higher testing rates than men in corresponding age groups, whereas this trend reversed in in the younger (<20) and older age groups (60-69 and 70-79), echoing trends observed in other European countries (46). These variations illustrate a complex relationship between age, gender/sex, and health-seeking behavior, calling for further investigations.

Age is a key factor in understanding COVID-19 gender/sex disparities. The influence of gender 293 294 norms on health outcomes varies across the life course (19, 28, 31), and the disparities in testing rates between men and women across different age groups likely reflect the evolving societal 295 296 roles and responsibilities (47). In the 20 to 40 age range, where gender differences in testing were 297 most pronounced, marked distinctions in family and employment domains are generally observed. Women are more likely to work in essential service sectors involving close contacts and limited 298 299 telecommuting options, such as in service and healthcare jobs (47-50), which may account for 300 their higher testing rates. Yet, this potential increased exposure did not translate into higher positivity rates when accounting for initial differences in testing, possibly attributable to greater 301 302 adherence to health recommendations and protective measures among women compared to men 303 (23, 26, 29, 49, 51). Additionally, women in this age group often bear a disproportionate burden 304 of unpaid care responsibilities, likely influencing their decisions regarding COVID-19 testing (29, 52). The observed higher testing rates in men aged 60 and above may be attributed to the 305

preferential ascertainment of severe cases (53), where individuals who are more likely, or perceived as more likely-due to early widely reported higher mortality rates in men-, to suffer from severe forms of infection tend to get tested more frequently. Although the ratios of positive tests were generally similar, women aged 60 and above were significantly less likely to test positive per test conducted compared to their male counterparts, highlighting possible differences in exposure.

Our study corroborates the well-established correlation between age and severe COVID-19 outcomes, with older age associated with an increased risk of hospitalization, ICU admissions, and mortality. Additionally, our data confirm that men face a higher risk of severe outcomes compared to women, aligning with previous research (54-56). Notably, women under the age of 60 and those aged 70 and above had a reduced risk of ICU admissions when hospitalized, suggesting possible variations in immune system responses, prevalence of comorbidities, healthseeking behaviors, or differences in treatment approaches between women and men.

Our findings are consistent with existing literature on the link between SEP and COVID-19 319 outcomes (1-5), highlighting the increased vulnerability of individuals residing in low SEP 320 321 neighborhoods. This vulnerability stems from a combination of factors, including limited access to 322 healthcare, higher exposure risks due to living and working conditions, occupational hazards, and 323 lifestyle habits, coupled with higher comorbidities rates (57). Previous studies show that those in 324 lower SEP areas experienced lower testing rates-particularly pronounced in the pandemic's early 325 stages-and faced elevated rates of case incidence, hospitalizations, and mortality, a trend reported globally (1-5, 9, 58-60). 326

As extensively documented in the literature and corroborated by our findings, men experienced 327 higher mortality rates related to COVID-19 compared to women (12, 13, 15-17, 23, 29, 61). Our 328 results outlined gender/sex disparities in mortality across SEP quintiles, particularly marked in the 329 330 lowest SEP neighborhoods. This suggests that men from socioeconomically deprived backgrounds may encounter cumulative disadvantages that amplify their health vulnerabilities 331 332 throughout their lives (62). Biological sex-related factors are thought to play a significant role in men's increased vulnerability to COVID-19, possibly mediated through hormonal and immune 333 response (29, 50). Mortality is also influenced by gendered practices and societal norms such as 334 expressions of masculinity, which intersect with various social determinants of health (50). These 335 336 include working in hazardous industries, engagement in risky health behaviors, and maintaining 337 lifestyles that lead to higher prevalences of chronic diseases (26, 28, 29, 63, 64), which are more common in socioeconomically disadvantaged populations (58). Beyond age, pre-existing medical 338 339 conditions such as obesity, diabetes, or chronic respiratory and cardiovascular diseases have 340 been described as major contributors to COVID-19 severity (65). Comparatively riskier health

behaviors among men, such as smoking, excessive alcohol consumption, and unhealthy diets, 341 342 combined with societal norms that valorize toughness and discourage timely medical care, are thought to contribute to their health vulnerabilities (16, 19, 26). Our findings align with existing 343 344 studies using an intersectional framework, which are notably concentrated in the US and often 345 emphasize ethnic/racial disparities alongside gender/sex, though not always directly correlating 346 these with socioeconomic class distinctions. Notably, a US study found that Black women 347 experienced higher mortality rates than White men, while Black men had the highest mortality rates (66). Another study exploring the combined effects of gender, SEP, and race/ethnicity 348 revealed that, compared to high SEP White women, low SEP White men experienced a mortality 349 rate 7.4 times higher, and 1.5 times higher compared to women in low SEP. Meanwhile, low SEP 350 351 Hispanic men faced the most significant disparity, with mortality rates 27 times higher than those 352 of high SEP White women (67).

Our study's strengths include the use of a neighborhood-based SEP indicator to capture potential 353 354 individual and local-level effects on outcomes, and the minimization of selection bias by using comprehensive surveillance data for the entire Canton of Vaud population. Although Vaud was 355 heavily impacted during the early stages of the pandemic, its diverse rural and urban population 356 profiles provide valuable insights that may reflect broader trends in Switzerland, despite some 357 regional variations. However, our analysis is limited by the absence of data on key individual-level 358 359 factors such as migration background status and ethnicity. Incorporating these factors could 360 areatly enrich our understanding, especially given that approximately one-third of Vaud's 361 population in 2020 held non-Swiss nationality (39), and ethnic minorities faced higher exposure and vulnerability to COVID-19 (60, 66, 68). Furthermore, disentangling the sources of disparities 362 between gender and sex is methodologically challenging when using administrative sex to 363 investigate women's and men's health outcomes. Nevertheless, our intersectional approach 364 facilitated the development of hypotheses about gendered mechanisms, which extend beyond 365 the traditional biological interpretations common in biomedical research. Another limitation 366 concerns hospitalization and ICU admission data, which may be subject to underreporting due to 367 368 challenges associated with identifying primary causes of hospitalization, especially among older adults with comorbidities (69). Moreover, deaths occurring outside clinical settings frequently 369 370 remain untested, complicating their classification as COVID-19 related (69, 70). Additionally, the reliance on residence location for the Swiss-SEP indicator may not accurately reflect an 371 372 individual's lifelong SEP, a common challenge with area-based indicators (71).

373 Conclusion

Our study within the Canton of Vaud highlighted the significant interplay of gender/sex, age, and
 SEP in shaping the epidemiology COVID-19. The intersectional analyses have revealed nuanced

disparities, notably the increased risk of mortality in men, particularly those from lower SEP neighborhoods. While no substantial gender/sex differences in testing outcomes were observed across SEP quintiles, important age-related variation emerged, with young adult women experiencing higher testing rates. These findings underscore the importance of adopting intersectional approaches in both epidemiological research and public health strategy development. Such approaches are necessary for developing more effective and equitable health responses.

- 383
- 384
- 385
- 386
- - -
- 387

388 References

Laajaj R, Webb D, Aristizabal D, Behrentz E, Bernal R, Buitrago G, et al. Understanding
 how socioeconomic inequalities drive inequalities in COVID-19 infections. Scientific Reports.
 (2022);12(1):8269.

392 2. Benita F, Rebollar-Ruelas L, Gaytán-Alfaro ED. What have we learned about 393 socioeconomic inequalities in the spread of COVID-19? A systematic review. Sustainable Cities 394 and Society. (2022);86:104158.

395 3. Vandentorren S, Smaïli S, Chatignoux E, Maurel M, Alleaume C, Neufcourt L, et al. The 396 effect of social deprivation on the dynamic of SARS-CoV-2 infection in France: a population-based 397 analysis. The Lancet public health. (2022);7(3):e240-e9.

4. Mongin D, Cullati S, Kelly-Irving M, Rosselet M, Regard S, Courvoisier DS.
Neighbourhood socio-economic vulnerability and access to COVID-19 healthcare during the first two waves of the pandemic in Geneva, Switzerland: A gender perspective. EClinicalMedicine.
(2022);46:101352.

402 5. Riou J, Panczak R, Althaus CL, Junker C, Perisa D, Schneider K, et al. Socioeconomic 403 position and the COVID-19 care cascade from testing to mortality in Switzerland: a population-404 based analysis. The Lancet Public Health. (2021);6(9):e683-e91.

405 6. Khazanchi R, Beiter ER, Gondi S, Beckman AL, Bilinski A, Ganguli I. County-Level 406 Association of Social Vulnerability with COVID-19 Cases and Deaths in the USA. J Gen Intern 407 Med. (2020);35(9):2784-7.

408
 7. Berchet C, Bijlholt J, Ando M. Socio-economic and ethnic health inequalities in COVID-19
 409 outcomes across OECD countries. (2023).

410 8. Jassat W, Ozougwu L, Munshi S, Mudara C, Vika C, Arendse T, et al. The intersection of
411 age, sex, race and socio-economic status in COVID-19 hospital admissions and deaths in South
412 Africa (with corrigendum). South African Journal of Science. (2022);118(5/6).

413 9. Khan MM, Odoi A, Odoi EW. Geographic disparities in COVID-19 testing and outcomes
414 in Florida. BMC Public Health. (2023);23(1):79.

415 10. Tudor Hart J. THE INVERSE CARE LAW. The Lancet. (1971);297(7696):405-12.

416 11. Corna LM. A life course perspective on socioeconomic inequalities in health: A critical
 417 review of conceptual frameworks. Advances in Life Course Research. (2013);18(2):150-9.

Thompson K, Vassallo A, Finfer S, Woodward M. Renewed rationale for sex-and genderdisaggregated research: A COVID-19 commentary review. Women's Health.
(2022);18:17455065221076738.

421 13. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and
422 gender on COVID-19 outcomes in Europe. Biology of Sex Differences. (2020);11(1):29.

423 14. Scully EP, Schumock G, Fu M, Massaccesi G, Muschelli J, Betz J, et al. Sex and Gender
424 Differences in Testing, Hospital Admission, Clinical Presentation, and Drivers of Severe
425 Outcomes From COVID-19. Open Forum Infectious Diseases. (2021);8(9).

Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al.
Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nature communications. (2020);11(1):1-10.

429 16. Bambra C, Albani V, Franklin P. COVID-19 and the gender health paradox. Scandinavian
430 Journal of Public Health. (2021);49(1):17-26.

431 17. Sharma G, Volgman AS, Michos ED. Sex Differences in Mortality From COVID-19
432 Pandemic. JACC: Case Reports. (2020);2(9):1407-10.

433 18. Bauer GR. Sex and Gender Multidimensionality in Epidemiologic Research. Am J
 434 Epidemiol. (2023);192(1):122-32.

Heise L, Greene ME, Opper N, Stavropoulou M, Harper C, Nascimento M, et al. Gender
inequality and restrictive gender norms: framing the challenges to health. The Lancet.
(2019);393(10189):2440-54.

438 20. Kaufman MR, Eschliman EL, Karver TS. Differentiating sex and gender in health research 439 to achieve gender equity. Bull World Health Organ. (2023);101(10):666-71.

Shannon G, Jansen M, Williams K, Cáceres C, Motta A, Odhiambo A, et al. Gender
equality in science, medicine, and global health: where are we at and why does it matter? Lancet.
(2019);393(10171):560-9.

Laster Pirtle WN, Wright T. Structural Gendered Racism Revealed in Pandemic Times:
Intersectional Approaches to Understanding Race and Gender Health Inequities in COVID-19.
Gender & Society. (2021);35(2):168-79.

23. Danielsen AC, Lee KM, Boulicault M, Rushovich T, Gompers A, Tarrant A, et al. Sex
disparities in COVID-19 outcomes in the United States: Quantifying and contextualizing variation.
Soc Sci Med. (2022);294:114716.

449 24. Clark C, Davila A, Regis M, Kraus S. Predictors of COVID-19 voluntary compliance 450 behaviors: An international investigation. Global Transitions. (2020);2:76-82.

451 25. Wenham C, Smith J, Morgan R. COVID-19: the gendered impacts of the outbreak. The 452 lancet. (2020);395(10227):846-8.

453 26. Ya'qoub L, Elgendy IY, Pepine CJ. Sex and gender differences in COVID-19: More to be 454 learned! American Heart Journal Plus: Cardiology Research and Practice. (2021);3:100011.

455 27. Groban L, Wang H, Sun X, Ahmad S, Ferrario CM. Is Sex a Determinant of COVID-19 456 Infection? Truth or Myth? Current Hypertension Reports. (2020);22(9):62.

Taslem Mourosi J, Anwar S, Hosen MJ. The sex and gender dimensions of COVID-19: A
narrative review of the potential underlying factors. Infection, Genetics and Evolution.
(2022);103:105338.

29. Díaz-Rodríguez N, Binkyte R, Bakkali W, Bookseller S, Tubaro P, Bacevičius A, et al.
Gender and sex bias in COVID-19 epidemiological data through the lens of causality. Information
Processing & Management. (2023);60(3):103276.

30. Youth Repeatedly Hospitalized for DKA: Proof of Concept for Novel Interventions in
 Children's Healthcare (NICH) | Diabetes Care.

31. Notarte KI, de Oliveira MHS, Peligro PJ, Velasco JV, Macaranas I, Ver AT, et al. Age, Sex
and Previous Comorbidities as Risk Factors Not Associated with SARS-CoV-2 Infection for Long
COVID-19: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine.
(2022);11(24):7314.

469 32. Collins PH. Intersectionality's Definitional Dilemmas. Annual Review of Sociology. 470 (2015);41(1):1-20.

33. Olanlesi-Aliu A, Tulli M, Kemei J, Bonifacio G, Reif LC, Cardo V, et al. A scoping review
on the operationalization of intersectional health research methods in studies related to the
COVID-19 pandemic. International Journal of Qualitative Studies on Health and Well-being.

474 (2024);19(1):2302305.

475 34. Molenaar J. Using an intersectional lens to understand the unequal impact of the COVID-476 19 pandemic. Bi-monthly report 5 September 2021. (2021).

477 35. Bauer GR. Incorporating intersectionality theory into population health research 478 methodology: Challenges and the potential to advance health equity. Social Science & Medicine. 479 (2014);110:10-7.

Giachino M, Valera CBG, Rodriguez Velásquez S, Dohrendorf-Wyss MA, Rozanova L,
Flahault A. Understanding the Dynamics of the COVID-19 Pandemic: A Real-Time Analysis of
Switzerland's First Wave. International Journal of Environmental Research and Public Health.
(2020);17(23):8825.

484 37. Office fédéral de la santé publique, Commission fédérale pour les vaccinations. COVID485 19 : stratégie de vaccination (2022) 29.11.2022. Available from:
486 https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-ausbrueche-

487 pandemien/2019-nCoV/impfstrategie-bag-ekif.pdf.download.pdf/strategie-de-vaccination-covid 488 19-ofsp-ekif.pdf.

489 38. EPICOVID, Direction Générale de la santé (DGS), Office du médecin cantonal. COVID-

490 19: Point épidémiologique – Situation au 28 juin 2021. Available from: 491 <u>https://infosan.vd.ch/fileadmin/2-</u>

492 <u>PUBLICATIONS/SANTE POPULATION/SSP 20210628 COVID Bulletin hebdomadaire epid</u>
 493 <u>emio.pdf</u>.

494 39. Statistique Vaud (2020). Population résidante permanente par âge exact_sexe et origine_ 495 Vaud 2017-2020 [Available from: https://www.vd.ch/themes/etat-droitfinances/statistique/statistiques-par-domaine/01-population/etat-et-structure-de-la-population. 496 40. Panczak R, Berlin C, Voorpostel M, Zwahlen M, Egger M. The Swiss neighbourhood index 497 of socioeconomic position: update and re-validation. Swiss Medical Weekly. (2023);153(1):40028. 498 Panczak R, Galobardes B, Voorpostel M, Spoerri A, Zwahlen M, Egger M. A Swiss 499 41. 500 neighbourhood index of socioeconomic position: development and association with mortality. J Epidemiol Community Health. (2012);66(12):1129-36. 501 R Core Team. R: A language and environment for statistical computing. In: Computing 502 42. 503 RFfS, editor. Vienna, Austria(2022). Ripley B, Venables B. Modern Applied Statistics with S. Fourth ed. New York: Springer; 504 43. (2022). 505 Heidari S, Babor TF, De Castro P, Tort S, Curno M. Sex and Gender Equity in Research: 506 44. rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev. (2016);1(1):2. 507 508 45. Fausto-Sterling A. Gender/Sex, Sexual Orientation, and Identity Are in the Body: How Did 509 They Get There? J Sex Res. (2019);56(4-5):529-55. Sobotka T, Brzozowska Z, Muttarak R, Zeman K, di Lego V. Age, gender and COVID-19 510 46. infections. medRxiv. (2020):2020.05.24.20111765. 511 47. Yavorsky JE, Qian Y, Sargent AC. The gendered pandemic: The implications of COVID-512 19 for work and family. Sociol Compass. (2021);15(6):e12881. 513 Kley S, Reimer T. Exploring the Gender Gap in Teleworking from Home. The Roles of 514 48. Worker's Characteristics, Occupational Positions and Gender Equality in Europe. Social 515 516 Indicators Research. (2023);168(1):185-206. Sant Fruchtman C, Fischer FB, Monzón Llamas L, Tavakkoli M, Cobos Muñoz D, Antillon 517 49. M. Did COVID-19 Policies Have the Same Effect on COVID-19 Incidence Among Women and 518 519 Men? Evidence From Spain and Switzerland. Int J Public Health. (2022);67:1604994. Morgan R, Baker P, Griffith DM, Klein SL, Logie CH, Mwiine AA, et al. Beyond a zero-sum 520 50. 521 game: how does the impact of COVID-19 vary by gender? Frontiers in Sociology. (2021):126. Galasso V. Pons V, Profeta P, Becher M, Brouard S, Foucault M. Gender differences in 522 51. COVID-19 attitudes and behavior: Panel evidence from eight countries. Proceedings of the 523 524 National Academy of Sciences. (2020):117(44):27285-91. 525 Bühler N, Pralong M, Rawlinson C, Gonseth S, D'Acremont V, Bochud M, et al. Caring 52. during COVID-19: Reconfigurations of gender and family relations during the pandemic in 526 527 Switzerland. Frontiers in Sociology. (2021);6:737619. Lipsitch M, Donnelly CA, Fraser C, Blake IM, Cori A, Dorigatti I, et al. Potential Biases in 528 53. Estimating Absolute and Relative Case-Fatality Risks during Outbreaks. PLoS Negl Trop Dis. 529 (2015);9(7):e0003846. 530 531 54. Hawkes S, Pantazis A, Purdie A, Gautam A, Kiwuwa-Muyingo S, Buse K, et al. Sex-532 disaggregated data matters: tracking the impact of COVID-19 on the health of women and men. 533 Econ Polit (Bologna). (2022);39(1):55-73. Pivonello R, Auriemma RS, Pivonello C, Isidori AM, Corona G, Colao A, et al. Sex 534 55. 535 Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger? Neuroendocrinology. (2021);111(11):1066-85. 536 Scully EP, Schumock G, Fu M, Massaccesi G, Muschelli J, Betz J, et al., editors. Sex and 537 56. gender differences in testing, hospital admission, clinical presentation, and drivers of severe 538 outcomes from COVID-19. Open forum infectious diseases; 2021: Oxford University Press US; 539 540 (2021)Published. 541 Acebillo-Baqué M, Maestripieri L. Intersectionality Theory and Its Application in the 57. COVID-19 Pandemics. In: Liamputtong P, editor. Handbook of Social Sciences and Global Public 542 543 Health. Cham: Springer International Publishing; (2023). p. 1189-211. 544 McGowan VJ, Bambra C. COVID-19 mortality and deprivation: pandemic, syndemic, and 58. endemic health inequalities. The Lancet Public Health. (2022);7(11):e966-e75. 545 Bambra C. Pandemic inequalities: emerging infectious diseases and health equity. 546 59. 547 International Journal for Equity in Health. (2022);21(1):6.

- 548 60. Khanijahani A, Iezadi S, Gholipour K, Azami-Aghdash S, Naghibi D. A systematic review 549 of racial/ethnic and socioeconomic disparities in COVID-19. International Journal for Equity in 550 Health. (2021);20(1):248.
- 551 61. Kim H, Fox AM, Kim Y, Kim R, Bae G, Kang M. Is the male disadvantage real? Cross-552 national variations in sex gaps in COVID-19 incidence and mortality. Glob Public Health. 553 (2021);16(12):1793-803.
- 554 62. Turrell G, Lynch JW, Leite C, Raghunathan T, Kaplan GA. Socioeconomic disadvantage 555 in childhood and across the life course and all-cause mortality and physical function in adulthood: 556 evidence from the Alameda County Study. Journal of Epidemiology and Community Health. 557 (2007);61(8):723-30.
- 558 63. Anderegg N, Panczak R, Egger M, Low N, Riou J. Survival among people hospitalized 559 with COVID-19 in Switzerland: a nationwide population-based analysis. BMC Med. 560 (2022);20(1):164.
- 561 64. Nikoloski Z, Alqunaibet AM, Alfawaz RA, Almudarra SS, Herbst CH, El-Saharty S, et al. 562 Covid-19 and non-communicable diseases: evidence from a systematic literature review. BMC 563 Public Health. (2021);21(1):1068.
- 65. Agodi A, Maugeri A, Favara G, Magnano San Lio R, Puglisi M, Sinatra D, et al. Gender
 differences in comorbidities of patients with COVID-19: An Italian local register-based analysis.
 Heliyon. (2023);9(7):e18109.
- 66. Rushovich T, Boulicault M, Chen JT, Danielsen AC, Tarrant A, Richardson SS, et al. Sex
 Disparities in COVID-19 Mortality Vary Across US Racial Groups. Journal of General Internal
 Medicine. (2021);36(6):1696-701.
- 570 67. Pathak EB, Menard JM, Garcia RB, Salemi JL. Joint Effects of Socioeconomic Position, 571 Race/Ethnicity, and Gender on COVID-19 Mortality among Working-Age Adults in the United 572 States. Int J Environ Res Public Health. (2022);19(9).
- 573 68. Irizar P, Pan D, Kapadia D, Bécares L, Sze S, Taylor H, et al. Ethnic inequalities in COVID-574 19 infection, hospitalisation, intensive care admission, and death: a global systematic review and 575 meta-analysis of over 200 million study participants. eClinicalMedicine. (2023);57.
- 576 69. Akter S. The gender gap in COVID-19 mortality in the United States. Feminist Economics. 577 (2021);27(1-2):30-47.
- 578 70. Riou J, Hauser A, Fesser A, Althaus CL, Egger M, Konstantinoudis G. Direct and indirect 579 effects of the COVID-19 pandemic on mortality in Switzerland. Nature Communications. 580 (2023);14(1):90.
- 581 71. Bryere J, Pornet C, Copin N, Launay L, Gusto G, Grosclaude P, et al. Assessment of the 582 ecological bias of seven aggregate social deprivation indices. BMC Public Health. 583 (2017);17(1):86.
- 584

Table 1 Distribution of age and socioeconomic position (SEP), stratified by gender/sex categories, Canton of Vaud surveillance data, from March2*, 2020 to June 27, 2021, Switzerland

	Population (N=815 300)		Total tests* (N = 885 925)		Positive tests (N = 96 963)		Hospitalisations (N = 6 356)		ICU admissions (N = 1 134)		Deaths (N = 1 175)	
	Women	Men	Women	Men	Women	Men	Women	Men	Women	Men	Women	Men
	N = 412 599	N = 402 701	N = 463 105	N = 422 820	N = 50 296	N = 46 667	N = 2 720	N = 3 636	N = 334	N = 800	N = 558	N = 617
Age grou	ips	1	•	1		1		1				
0-9	42 502	44 319	10 675	12 225	COO (4, OO()	C40 (4 40()) 30 (1.1%)	31 (0.9%)	0 (0%)	1 (0.1%)	0 (0%)	0 (0%)
	(10%)	(11%)	(2.3%)	(2.9%)	620 (1.2%)	649 (1.4%)						
10-19	44 291	47 101	47 039	47 542	4 644	4 743	EQ (1 99/)	48 (1.3%)	1 (0.3%)	1 (0.1%)	0 (0%)	0 (0%)
	(11%)	(12%)	(10%)	(11%)	(9.2%)	(10%)	50 (1.8%)					
20-29	52 178	54 565	84 209	76 947	8 854	7 987	128	69 (1.9%)	8 (2.4%)	5 (0.6%)	0 (0%)	1 (0.3%)
	(13%)	(14%)	(18%)	(18%)	(18%)	(17%)	(4.7%)					
30-39	59 329	59 317	94 883	81 253	8 799	7 896	173	121	13	12	0 (0%)	0 (0%)
	(14%)	(15%)	(20%)	(19%)	(17%)	(17%)	(6.4%)	(3.3%)	(3.9%)	(1.5%)	0 (0%)	
40-49	59 869	58 157	74 146	67 652	8 410	7 387	160	250	15	52	1 (0.3%)	1 (0.3%)
	(14%)	(15%)	(16%)	(16%)	(17%)	(16%)	(5.9%)	(6.9%)	(4.5%)	(6.5%)		
50-59	57 692	56 987	62 506	59 343	7 692	7 494	299	541	60	147	3 (0.9%)	5 (1.3%)
	(14%)	(14%)	(13%)	(14%)	(15%)	(16%)	(11%)	(15%)	(18%)	(18%)		
60-69	40 758	38 247	36 464	37 232	4 260	4 734	384	740	88	238	13 (4.1%)	27 (6.8%)
	(9.8%)	(9.6%)	(7.9%)	(8.8%)	(8.5%)	(10%)	(14%)	(20%)	(26%)	(30%)		
70-79	34 053	27 488	25 042	23 742	2 967	3 170	542	873	93	242	54 (17%)	103 (26%)
	(8.2%)	(6.9%)	(5.4%)	(5.6%)	(5.9%)	(6.8%)	(20%)	(24%)	(28%)	(30%)		
80+	24 246	14 201	28 141	16 884	4 050	2 607	954	963	56 102	102	246	259 (65%)
	(5.8%)	(3.5%)	(6.1%)	(4.0%)	(8.1%)	(5.6%)	(35%)	(26%)	(17%)	(17%) (13%)	(78%)	


Quintile of SEP									N = 317	N = 396		
Q1	83 022	80 913	79 987	74 721	10 334	9 382					EQ (169/)	02 (220/)
(lowest)	(20%)	(20%)	(17%)	(18%)	(21%)	(20%)	NA		NA	NA	50 (16%)	92 (23%)
Q2	82 756	80 512	88 181	80 457	10 560	9 708					78 (24 %)	72 (18%)
	(20%)	(20%)	(19%)	(19%)	(21%)	(21%)					70 (24 %)	
Q3 Q4	82 951	80 319	95 105	83 934	10 649	9 935		NA			69 (22%)	88 (22%)
	(20%)	(20%)	(21%)	(20%)	(21%)	(21%)		///4			09 (22 /0)	00 (22 /0)
	83 236	79 726	101 244	92 853	9 927	9 226					56 (18%)	77 (20%)
	(20%)	(20%)	(22%)	(22%)	(20%)	(20%)					50 (10%)	11 (2076)
Q5	82 953	78 912	98 588	90 855	8 826	8 416					64 (20%)	67 (17%)
(highest)	(20%)	(20%)	(21%)	(21%)	(18%)	(18%)					04 (20%)	07 (17%)


Notes: n (%); SEP = socioeconomic position; *NA* = Not Applicable. Death's distribution across SEP quantiles only includes geocoded notifications. * For total tests, period goes from May 27, 2020, to June 27, 2021.

Figure

[Fig. 1 – Weekly incidence rate overtime]


Figure 1 – Weekly incidence of COVID-19 outcomes per 100 000, stratified by gender/sex, Canton of Vaud surveillance data 2020-2021, Switzerland





[Fig. 2 – Cumulative incidence across SEP and age groups]

Figure 2 – Cumulative incidence of outcomes between March 2nd, 2020 and June 27, 2021* per 100 000, stratified by gender/sex, across age groups and quintiles of socio-economic position, Canton of Vaud surveillance data 2020-2021, Switzerland




Notes: **Panel A** indicates the cumulative incidences of outcomes stratified by gender/sex across age groups, while **Panel B** displays incidences across quintiles of socioeconomic position (SEP). The SEP indicator was not derived for hospitalization and ICU admissions, as only the ZIP code was available for these outcomes.

For visual clarity, the highest incidence point within each category have been brought to the foreground. *The period considered covered 57 weeks for total tests, and 69 weeks for the other outcomes of interest.

[Fig. 3 – IRR of tests and positive tests]


Figure 3– Incidence rate ratios (IRR) of gender/sex (ref.: men) for number of tests and of positive tests, stratified by age groups (upper part), and quintiles of socio-economic position (SEP, lower part), using general population (left and center panel) and total number of tests (right panel) as denominator, Canton of Vaud surveillance data 2020-2021, Switzerland



Confidence interval level at 0.95

[Fig. 4 – IRR of hospitalisations]

Figure 4 – Incidence rate ratios (IRR) of gender/sex (ref.: men) for hospitalization (upper panel) and ICU admission (lower panel) stratified by age groups, using general population as offset (panel A), and ICU admission per hospitalisations (panel B), Canton of Vaud surveillance data 2020-2021, Switzerland



[Fig. 5 – IRR of deaths]

Figure 5 – Incidence rate ratios (IRR) of gender/sex (ref.: men) for death, by age groups (blue coefficients), and quintiles of socio-economic position (SEP, red coefficients), using general population as offset, Canton of Vaud surveillance data 2020-2021, Switzerland

